Contact
searchSearch
HMP Global
Login
Quiz

AI Assistance for Immunohistochemistry Assessment of Breast Cancer

06/13/2025

Related Content

Sunil Badve, MD
Conference Coverage
Baseline sTILs as Predictors of Pathologic Response in HER2-Positive Breast Cancer
12/23/2025
Sunil Badve, MD
Sunil Badve, MD, discusses secondary analysis results from the CompassHER2 pCR trial which demonstrated that baseline sTILs were associated with pathologic complete response following preoperative trastuzumab plus pertuzumab and taxane-based...
Sunil Badve, MD, discusses secondary analysis results from the CompassHER2 pCR trial which demonstrated that baseline sTILs were associated with pathologic complete response following preoperative trastuzumab plus pertuzumab and taxane-based...
Sunil Badve, MD, discusses...
12/23/2025
Oncology
Matteo Lambertini, MD, PhD
Conference Coverage
Aromatase Inhibitor Therapy Improves Long-Term Survival in HR-Positive, HER2-Positive Early Breast Cancer
12/18/2025
Matteo Lambertini, MD, PhD
Matteo Lambertini, MD, PhD, discusses 10-year analysis results from the ALTTO trial evaluating the comparative effectiveness of aromatase inhibitors versus selective estrogen receptor modulators as adjuvant endocrine therapy in HR-positive,...
Matteo Lambertini, MD, PhD, discusses 10-year analysis results from the ALTTO trial evaluating the comparative effectiveness of aromatase inhibitors versus selective estrogen receptor modulators as adjuvant endocrine therapy in HR-positive,...
Matteo Lambertini, MD, PhD,...
12/18/2025
Oncology
Conference Coverage
Gedatolisib-Based Doublet and Triplet Regimens for PIK3CA-Wild-Type Advanced Breast Cancer
12/12/2025
Stephanie Holland
Updated results from the phase 3 VIKTORIA-1 trial indicate that adding gedatolisib to fulvestrant ± palbociclib yields promising clinical efficacy and safety in HR-positive, HER2-negative, PIK3CA-wild-type advanced breast cancer, offering a...
Updated results from the phase 3 VIKTORIA-1 trial indicate that adding gedatolisib to fulvestrant ± palbociclib yields promising clinical efficacy and safety in HR-positive, HER2-negative, PIK3CA-wild-type advanced breast cancer, offering a...
Updated results from the phase 3...
12/12/2025
Oncology
Conference Coverage
Baseline Stromal Tumor-Infiltrating Lymphocytes as Predictors of Pathologic Response in HER2-Positive Breast Cancer
12/12/2025
Stephanie Holland
According to secondary analysis results from the CompassHER2 pCR trial, baseline stromal tumor-infiltrating lymphocytes were associated with pCR following preoperative trastuzumab plus pertuzumab and taxane-based therapy among patients with...
According to secondary analysis results from the CompassHER2 pCR trial, baseline stromal tumor-infiltrating lymphocytes were associated with pCR following preoperative trastuzumab plus pertuzumab and taxane-based therapy among patients with...
According to secondary analysis...
12/12/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use